AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysGlobeNewsWire · Oct 7, 2026
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense PotentialGlobeNewsWire · Oct 5, 2026
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline DataGlobeNewsWire · Oct 1, 2026
Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers paceProactive Investors · Sep 30, 2026
AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoGlobeNewsWire · Sep 30, 2026
Ondine Biomedical pauses trading to raise fresh investment after positive phase III resultProactive Investors · Sep 30, 2026AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.17 | -$0.43 | Miss |
| May 15, 2026 | -$1.08 | -$0.69 | Beat |
| Mar 27, 2026 | -$0.94 | -$1.36 | Miss |
| Nov 17, 2025 | -$0.97 | -$1.57 | Miss |
| Aug 14, 2025 | -$8.00 | -$3.68 | Beat |
| May 14, 2025 | -$8.00 | -$5.00 | Beat |